ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q3 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $2.93 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Texas AG Paxton announces ongoing investigation into Carnival over data breach
• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ